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SHORT COMMUNICATION
Abstract: To prevent side effects of excessive accumulation of iron in the body, chelation
therapy is recommended in transfusion-dependent patients. The reaction between deferiprone
and iron to form a complex red substance can be described as 3 molecules of the chelator,
deferiprone, reacting with a molecule of iron. However, the actual mechanism of the
deferiprone – iron binding reaction is not well understood. A quantum chemical analysis of
the deferiprone – iron binding reaction was performed, focusing on the reaction between
1 molecule of deferiprone and 1 molecule of iron. The two main alternative pathways for the
deferiprone – iron binding reaction were shown to be C-C cleavage and C-O cleavage. The
required energy for complex formation in C-C cleavage was less than for C-O cleavage. The
total energy requirement for C-C cleavage was negative, implying that this reaction can occur
without any external energy source. The resulting complex fits the reported tertiary structure
model for the deferiprone – iron complex
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Introduction
To prevent the side effects of excessive accumulation of iron in the body, chelation
therapy is recommended in transfusion-dependent patients (Ceci et al 2003; Marx
2003). Pharmacologically, the tight binding of chelators to iron blocks the iron’s
ability to catalyze redox reactions (Ceci et al 2003). Consequently, a chelator that
binds to all binding sites of the iron completely inactivates the free iron.
The two common iron-chelating agents available for the treatment of iron overload
are deferoxamine and deferiprone (Ceci et al 2003). Deferiprone is the only orally
active iron-chelating drug to be used therapeutically in conditions of transfusional
iron overload (Nagarajan et al 2005). It is indicated as a second-line treatment in
patients with thalassaemia major, for whom deferoxamine therapy is contraindicated,
or in patients with serious toxicity to deferoxamine therapy (Ceci et al 2003).
The reaction between deferiprone and iron to form a complex red substance can
be described as three molecules of the chelator, deferiprone, reacting with one
molecule of iron. However, the actual mechanism of the deferiprone–iron binding
reaction is not well described. This paper reports a quantum chemical analysis of the
deferiprone – iron binding reaction.
Materials and methods
Alternative pathways for deferiprone–iron binding reaction
Deferiprone is a bidentate chelator: a single molecule can interact with only two of
the coordination sites on iron (Figure 1). Therefore, 3 molecules are required for
complete binding. This study focused on the reaction between 1 molecule of
deferiprone and 1 molecule of iron. The two main alternative pathways for the
deferiprone – iron binding reaction are C-C cleavage and C-O cleavage.
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Quantum chemical analysis for bonding
energy
The quantum chemical analysis for bonding energy of
deferiprone (C7H9NO2) was performed according to
classical bonding theory (Goldberg 1989). The resulting
complexes between deferiprone and iron from each
alternative reaction pathway were analyzed, and the required
energy for complex formation by each pathway was
compared.
Results
The details and the required energy for complex formation
in C-C cleavage and C-O cleavage pathways are presented
in Table 1. The required energy for complex formation in
C-C cleavage was less than for C-O cleavage.
Discussion
The recommended treatment for many congenital
hematological disorders, especially for thalassaemia major,
is regular blood transfusions. These transfusions lead to the
harmful accumulation of iron in the body and subsequent
hemochromatosis (Ceci 2003). Iron chelation is required in
these cases. Deferiprone is a new oral iron-chelating agent
which is effective in removing iron from the heart, which is
the target organ of iron toxicity and mortality in iron-loaded
thalassaemia patients (Kontoghiorghes et al 2003).
Biochemically, deferiprone is a bidentate chelator. Because
a single molecule can interact with only 2 of the coordination
sites on iron, 3 molecules are required for complete binding
(Merson and Oliver 2002; Kontoghiorghes et al 2003). The
crystal structure of deferiprone is orthorhombic (Chan et al
1992). In each molecule, the OH group and the CO oxygen
are insignificantly intramolecularly hydrogen-bonded (Chan
et al 1992). The fundamental intermolecular and
insignificant intramolecular hydrogen-bonded dimer
structure of deferiprone is maintained, but is distorted and
supplemented by hydrogen bonds between the CO oxygen
of each deferiprone molecule and the OH group of one
formic acid molecule (Chan et al 1992).
Tam et al (2003) noted that future chelator research
would focus on the application of chelators for other diseases
and the development of new effective chelators. Evidence
on the differences in the mode of action of chelators, and
molecular structure – activity correlations, is valuable for
future metallopharmacological studies (Kontoghiorghes et
al 2004). Therefore, research on the biochemical reaction
in deferiprone – iron complex formation can provide useful
information for further bio-iron research. In the present
study, 2 possible mechanisms are proposed for deferiprone –
 iron complex formation. The energy required for C-C
cleavage was much less than for C-O cleavage. In addition,
the total energy requirement for C-C cleavage was negative,
implying that this reaction can occur without any external
energy source. The resulting complex fits the reported
tertiary structure model for the deferiprone – iron complex
(Wiwanitkit 2005).
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Figure 1 The alternative pathways for the deferiprone–iron binding reaction.
Table 1 Details and required energy for complex formation in
C-C cleavage and C-O cleavage pathways
Items C-C cleavage C-O cleavage
Bond breaking* 1 C=C, 1 C=O 1 C=O
Bond forming† 2 C-O, 1 C-H, 1 C-C, 1 C-O, 1 C-Fe
2+
1 C-Fe2+
Accumulated energy 146 kcal/mol +  177 kcal/mol
177 kcal/mol
Released energy (2 × 83 kcal/mol) +  83 kcal/mol + 1 eV
100 kcal/mol + 
80 kcal/mol + 1 eV
Required energy‡ –23 kcal/mol – 1 eV 94 kcal/mol – 1 eV
*bond-breaking accumulated energy
†bond-forming released energy
‡required energy = accumulated energy – released energy
Abbreviations: eV, electron volt.International Journal of Nanomedicine 2006:1(1) 113
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